VMAT technique enables concomitant radiotherapy of prostate cancer and pelvic bone metastases

References

• Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: Identifying prognostic groups using recursive partitioning. J Urol 2003;169: 164–9.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467–79.
   PubMed Web of Science ®Google Scholar
• Sweeney C, Chen Y, Carducci M, Liu G, Jarrard D, Eisenberger M, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 2014;32:5s (suppl; abstr LBA2).
   Google Scholar
• Oefelein MG. Prognostic significance of obstructive uropathy in advanced prostate cancer. Urology 2004;63:1117–21.
   PubMed Web of Science ®Google Scholar
• Perez CA, Cosmatos D, Garcia DM, Eisbruch A, Poulter CA. Irradiation in relapsing carcinoma of the prostate. Cancer 1993;71:1110–22.
   PubMed Web of Science ®Google Scholar
• Fogarty GB, Ng D, Liu G, Haydu LE, Bhandari N. Volumetric modulated arc therapy is superior to conventional intensity modulated radiotherapy – a comparison among prostate cancer patients treated in an Australian centre. Radiat Oncol 2011;6:108.
   PubMedGoogle Scholar
• Aznar MC, Petersen PM, Logadottir A, Lindberg H, Korreman SS, Kjaer-Kristoffersen F, et al. Rotational radiotherapy for prostate cancer in clinical practice. Radiother Oncol 2010;97:480–4.
   PubMed Web of Science ®Google Scholar
• Pesce GA, Clivio A, Cozzi L, Nicolini G, Richetti A, Salati E, et al. Early clinical experience of radiotherapy of prostate cancer with volumetric modulated arc therapy. Radiat Oncol 2010;5:54.
   PubMed Web of Science ®Google Scholar
• Clark GM, Popple RA, Young PE, Fiveash JB. Feasibility of single-isocenter volumetric modulated arc radiosurgery for treatment of multiple brain metastases. Int J Radiat Oncol Biol Phys 2010;76:296–302.
   PubMed Web of Science ®Google Scholar
• Bignardi M, Cozzi L, Fogliata A, Lattuada P, Mancosu P, Navarria P, et al. Critical appraisal of volumetric modulated arc therapy in stereotactic body radiation therapy for metastases to abdominal lymph nodes. Int J Radiat Oncol Biol Phys 2009;75:1570–7.
   PubMed Web of Science ®Google Scholar
• Kuijper IT, Dahele M, Senan S, Verbakel WF. Volumetric modulated arc therapy versus conventional intensity modulated radiation therapy for stereotactic spine radiotherapy: A planning study and early clinical data. Radiother Oncol 2010;94:224–8.
   PubMed Web of Science ®Google Scholar
• Macdougall ND, Dean C, Muirhead R. Stereotactic body radiotherapy in prostate cancer: Is rapidarc a better solution than cyberknife? Clin Oncol (R Coll Radiol) 2014; 26:4–9.
   PubMed Web of Science ®Google Scholar
• Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, et al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: Results of a matched analysis. Eur Urol 2011;59:832–40.
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Kairemo K. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 2014;35:221–30.
   PubMed Web of Science ®Google Scholar
• Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010;76:S123–9.
   PubMed Web of Science ®Google Scholar
• Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys 2010;76:S116–22.
   PubMed Web of Science ®Google Scholar
• Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76:S10–9.
   PubMed Web of Science ®Google Scholar
• Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, et al. RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009;74:383–7.
   PubMed Web of Science ®Google Scholar
• Yoo S, Wu QJ, Lee WR, Yin FF. Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes. Int J Radiat Oncol Biol Phys 2010; 76:935–42.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124–9.
   PubMed Web of Science ®Google Scholar
• Kairemo K, Rasulova N, Kiljunen T, Partanen K, Kangasmäki A, Joensuu T. PET/CT dose planning for volumetric modulated arc radiation therapy (VMAT) – comparison with conventional approach in advanced prostate cancer patients. Curr Radiopharm 2014 (in press).
   Google Scholar